|Bid||1.690 x 0|
|Ask||1.700 x 0|
|Day's Range||1.620 - 1.740|
|52 Week Range||1.600 - 2.480|
|PE Ratio (TTM)||13.15|
|Forward Dividend & Yield||0.04 (2.11%)|
|1y Target Est||1.30|
April 18 (Reuters) - China NT Pharma Group Co Ltd: * PFENEX AND NT PHARMA ENTER INTO A DEVELOPMENT AND LICENSE AGREEMENT FOR PFENEX'S PF708 THERAPEUTIC EQUIVALENT CANDIDATE TO FORTEO® * PFENEX INC - PFENEX ...
SAN DIEGO and HONG KONG, April 18, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX) and China NT Pharma Group Company Limited (NT Pharma) (1011.HK) today announced an agreement under which Pfenex granted NT Pharma non-exclusive development and exclusive commercialization rights to PF708, a teriparatide therapeutic equivalent candidate to Eli Lilly & Company's Forteo®, in Mainland China, Hong Kong, Singapore, Malaysia and Thailand. In accordance with the agreement, Pfenex received a payment of $2.5 million upon signing of the agreement and may be eligible to receive additional payments of up to $22.5 million based on the achievement of certain development, regulatory, and sales-related milestones.
April 6 (Reuters) - China NT Pharma Group Co Ltd: * CHIU YU KANG RESIGNED AS CHIEF FINANCIAL OFFICER * APPOINTS WANG FEI AS CFO Source text for Eikon: Further company coverage:
March 27 (Reuters) - China Nt Pharma Group Co Ltd: * FY REVENUE RMB604.8 MILLION VERSUS RMB359.6 MILLION * FY NET PROFIT ATTRIBUTABLE RMB165.2 MILLION VERSUS RMB116.2 MILLION * FINAL DIVIDEND OF HK3.5 ...
Dec 15 (Reuters) - China Nt Pharma Group Co Ltd: * ENTERS DEAL TO TERMINATE SALES & PROMOTION DEAL, CO TO CEASE LIBOD SALES & PROMOTION FROM DEC. 31, 2017 Source text for Eikon: Further company coverage: ...